HDAC6 and Charcot-Marie-Tooth disease type 2D: Together, these results provide compelling evidence that axonal transport deficits arising from increased α-tubulin deacetylation contribute to the pathophysiology of certain forms of CMT2D, and that the deacetylases HDAC6 and SIRT2 may be actionable therapeutic targets.